Aktienanalyse zu Aldeyra Therapeutics Inc (ALDX)ALDXAldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Aldeyra Therapeutics Inc (ALDX) is not a good buy right now. The current price is $0.5832, and the stock has dropped 88.15% over the past year, indicating severe long-term weakness. Additionally, the RSI is at 28.693, suggesting the stock is oversold but may continue to decline. The main risk is the FDA's rejection of its dry eye treatment, which led to a 75% drop in stock price, reflecting significant investor concerns about the company's future viability.

5 analysts cover ALDX: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.50.